| 產(chǎn)品編號(hào) | bsm-33195M-Gold |
| 英文名稱 | Mouse Anti-Survivin/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的細(xì)胞凋亡抑制因子單克隆抗體 |
| 別 名 | API4; API-4; API 4; Survivin variant 3 alpha; Apoptosis Inhibitor 4; Apoptosis inhibitor survivin; Apoptosis inhibitor4; Baculoviral IAP repeat containing 5; Baculoviral IAP repeat containing protein 5; Baculoviral IAP repeat-containing protein 5; BIRC 5; BIRC5; BIRC-5; EPR 1; EPR-1; IAP4; IAP-4; IAP 4; SVV; TIAP; BIRC5_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 細(xì)胞凋亡 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號(hào) | Mix-mA? |
| 交叉反應(yīng) | Human, (predicted: Rat, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 16kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Survivin |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein G |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: May play a role in neoplasia. May counteract a default induction of apoptosis in G2/M phase. Interacts with tubulin. Inhibitor of caspase-3 and caspase-7. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Belongs to the IAP family. Function: Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Subunit: Monomer or homodimer. Exists as a homodimer in the apo state and as a monomer in the CPC-bound state. The monomer protects cells against apoptosis more efficiently than the dimer. Only the dimeric form is capable of enhancing tubulin stability in cells. When phosphorylated, interacts with HBXIP; the resulting complex binds pro-CASP9, as well as active CASP9, but much less efficiently. Component of the chromosomal passenger complex (CPC) composed of at least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB and AURKC. Interacts with JTB. Interacts with CDCA8 and INCENP; interaction is direct. Interacts with EVI5. Interacts with GTP-bound RAN in both the S and M phases of the cell cycle. Interacts with USP9X. Interacts with tubulin. Interacts with BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The monomeric form interacts with XIAP/BIRC4. Both the dimeric and monomeric form can interact with DIABLO/SMAC. Interacts with BIRC6/bruce. Subcellular Location: Cytoplasm. Nucleus. Chromosome. Chromosome, centromere. Cytoplasm, cytoskeleton, spindle. Chromosome, centromere, kinetochore. Midbody. Note=Localizes on chromosome arms and inner centromeres from prophase through metaphase. Localizes to kinetochores in metaphase, distributes to the midzone microtubules in anaphase and at telophase, localizes exclusively to the midbody. Colocalizes with AURKB at mitotic chromosomes. Acetylation at Lys-129 directs its localization to the nucleus by enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated nuclear export. Tissue Specificity: Expressed only in fetal kidney and liver, and to lesser extent, lung and brain. Abundantly expressed in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in high-grade lymphomas. Also expressed in various renal cell carcinoma cell lines. Post-translational modifications: Ubiquitination is required for centrosomal targeting. In vitro phosphorylation at Thr-117 by AURKB prevents interaction with INCENP and localization to mitotic chromosomes. Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti-apoptotic activities. Acetylation at Lys-129 by CBP results in its homodimerization, while deacetylation promotes the formation of monomers which heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The acetylated form represses STAT3 transactivation. The dynamic equilibrium between its acetylation and deacetylation at Lys-129 determines its interaction with XPO1/CRM1, its subsequent subcellular localization, and its ability to inhibit STAT3 transactivation. Similarity: Belongs to the IAP family. Contains 1 BIR repeat. Database links: Entrez Gene: 332 Human Entrez Gene: 11799 Mouse Omim: 603352 Human SwissProt: O15392 Human SwissProt: O70201 Mouse Unigene: 514527 Human Unigene: 8552 Mouse Unigene: 54471 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Survivin是目前發(fā)現(xiàn)的最強(qiáng)的凋亡抑制因子，存活蛋白是細(xì)胞凋亡抑制基因家族中的一個(gè)新成員，主要表達(dá)于細(xì)胞周期中的G2/M期，在許多惡性腫瘤組織中均有表達(dá)，主要用于各種惡性腫瘤的研究。 是細(xì)胞凋亡的一種抑制因子、參與細(xì)胞凋亡調(diào)控，可以用于各種惡性腫瘤的細(xì)胞凋亡的研究。Survivin具有腫瘤特異性，只表達(dá)于腫瘤和胚胎組織，且與腫瘤細(xì)胞的分化增殖及浸潤轉(zhuǎn)移密切相關(guān). |
